<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04816643</url>
  </required_header>
  <id_info>
    <org_study_id>C4591007</org_study_id>
    <secondary_id>2020-005442-42</secondary_id>
    <nct_id>NCT04816643</nct_id>
  </id_info>
  <brief_title>A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults</brief_title>
  <official_title>PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN AND YOUNG ADULTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioNTech SE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BioNTech SE</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2/3 study in healthy children and young adults.&#xD;
&#xD;
      Dependent upon safety and/or immunogenicity data generated during the course of this study,&#xD;
      and the resulting assessment of benefit-risk, the safety, tolerability, and immunogenicity of&#xD;
      BNT162b2 in participants &lt;6 months of age may subsequently be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 Dose-Finding&#xD;
&#xD;
      Is the open-label dose-finding portion of the study that will evaluate safety, tolerability,&#xD;
      and immunogenicity of BNT162b2 administered on a 2-dose (separated by approximately 21 days)&#xD;
      schedule in up to 3 age groups (participants ≥5 to &lt;12 years, ≥2 to &lt;5 years, and ≥6 months&#xD;
      to &lt;2 years of age).&#xD;
&#xD;
      Dose finding is being initiated in this study in participants ≥5 to &lt;12 years of age based on&#xD;
      the acceptable blinded safety assessment of the 30-µg dose in 12- to 15-year-olds in the&#xD;
      C4591001 study.&#xD;
&#xD;
      The purpose of Phase 1 is to identify preferred dose level(s) of BNT162b2 from up to 3&#xD;
      different dose levels in each age group.&#xD;
&#xD;
      Dependent upon safety and/or immunogenicity data generated during the course of this study,&#xD;
      it is possible that dose levels may not be started, may be terminated early, and/or may be&#xD;
      added with dose levels below the lowest stated dose.&#xD;
&#xD;
      Participants will have blood drawn prior to both Dose 1 and Dose 2 and 7 days after Dose 2 to&#xD;
      assess for immunogenicity to determine the final BNT162b2 dose level for the Phase 2/3.&#xD;
&#xD;
      Phase 1 Lower-Dose Evaluation&#xD;
&#xD;
      Is the open-label lower-dose evaluation portion of the study that will evaluate safety,&#xD;
      tolerability, and immunogenicity of BNT162b2 on a 2-dose (separated by approximately 21 days)&#xD;
      schedule in up to 3 age groups (participants ≥5 to &lt;12 years, 12 to &lt;16 years, and 16 to &lt;30&#xD;
      years of age).&#xD;
&#xD;
      The purpose of the Phase 1 lower-dose evaluation is to evaluate safety and immunogenicity of&#xD;
      BNT162b2 from up to 2 different dose levels in each age group.&#xD;
&#xD;
      Participants will have blood drawn prior to both Dose 1 and Dose 2 and 7 days after Dose 2 to&#xD;
      assess immunogenicity to determine the selected BNT162b2 dose level for the Phase 2/3&#xD;
      lower-dose evaluation portion of the study.&#xD;
&#xD;
      Phase 2/3 Selected-Dose&#xD;
&#xD;
      Is the portion of the study that will evaluate the safety, tolerability, and immunogenicity&#xD;
      of the selected dose level in each age group at the selected dose level from Phase 1 dose&#xD;
      finding, with a total of approximately 6750 participants as an additional 2250 participants&#xD;
      will be included to enlarge the size of the pediatric safety database. Participants will be&#xD;
      randomized in a 2:1 ratio to receive active vaccine or placebo.&#xD;
&#xD;
      Approximately 450 participants (300 in the active vaccine group and 150 in the placebo group)&#xD;
      randomized in each age group in this phase will contribute to the immunobridging analysis at&#xD;
      1 month after Dose 2 and will contribute to the overall analysis of the persistence of immune&#xD;
      response at 6 months after Dose 2. These participants will be enrolled from both US and EU&#xD;
      sites to ensure this subset is representative of the whole study.&#xD;
&#xD;
      For the persistence time points of 12 and 24 months after Dose 2, approximately 70&#xD;
      participants from each age group in the original BNT162b2 group will have an immunogenicity&#xD;
      blood draw in order to contribute to the analysis. All approximately 6750 participants will&#xD;
      contribute to the VE analysis for conditional VE and asymptomatic infection. Efficacy will be&#xD;
      evaluated within or across age groups in which immunobridging is successful, depending on&#xD;
      accrual of a sufficient number of cases in those age groups.&#xD;
&#xD;
      At designated US sites, an additional optional whole blood sample of approximately 10 mL will&#xD;
      be obtained prior to Dose 1 and at 7 days and 6 months after Dose 2 from up to approximately&#xD;
      60 participants ≥10 years of age. These samples will be used on an exploratory basis to&#xD;
      investigate the postvaccination cell-mediated immune response at these time points.&#xD;
&#xD;
      Phase 2/3 Lower-Dose Evaluation&#xD;
&#xD;
      Is the open-label portion of the study that will evaluate the safety, tolerability, and&#xD;
      immunogenicity of the selected dose level in each age group from the Phase 1 lower-dose&#xD;
      evaluation, with a total of approximately 900 active participants.&#xD;
&#xD;
      Approximately 300 active participants in each age group in this phase will contribute to the&#xD;
      immunobridging analysis at 1 month after Dose 2 and the overall analysis of the persistence&#xD;
      of immune response at 6 months after Dose 2. These participants will be enrolled from both US&#xD;
      and EU sites to ensure this subset is representative of the whole study.&#xD;
&#xD;
      Phase 2/3 Obtaining Serum Samples for Potential Troponin I Testing&#xD;
&#xD;
      If testing of troponin I levels in individuals who did not receive BNT162b2 indicates that&#xD;
      troponin I level could be a reliable indicator of potential subclinical myocarditis,&#xD;
      obtaining serum samples for potential troponin I testing during the period of increased risk&#xD;
      of clinical myocarditis may help characterize the absence/presence and frequency of&#xD;
      subclinical myocarditis. To assess, an additional group of participants will be included: 5&#xD;
      to &lt;12 years: 750 participants randomized 2:1 to receive BNT162b2 10 µg or placebo, and 500&#xD;
      participants 12 to &lt;16 years of age: open-label receipt of BNT162b2 30 µg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Anticipated">July 23, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 23, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants in Phase 1 reporting local reactions</measure>
    <time_frame>for 7 days after Dose 1 and Dose 2</time_frame>
    <description>Pain or tenderness at the injection site, redness and swelling as reported on electronic diaries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants in Phase 1 reporting systemic events</measure>
    <time_frame>for 7 days after Dose 1 and Dose 2</time_frame>
    <description>Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened join pain, decreased appetite drowsiness, and irritability as reported on electronic diaries</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants in Phase 1 reporting adverse events</measure>
    <time_frame>from Dose 1 through 1 month after the last dose</time_frame>
    <description>As elicited by investigational site staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants in Phase 1 reporting serious adverse events</measure>
    <time_frame>from Dose 1 through 6 months after the last dose</time_frame>
    <description>As elicited by investigational site staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants in Phase 2/3 reporting local reaction</measure>
    <time_frame>for 7 days after Dose 1 and Dose 2</time_frame>
    <description>Pain or tenderness at the injection site, redness and swelling as reported on electronic diaries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants in Phase 2/3 reporting systemic events</measure>
    <time_frame>for 7 days after Dose 1 and Dose 2</time_frame>
    <description>Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain, decreased appetite, drowsiness, and irritability as reported on electronic diaries</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants in Phase 2/3 reporting adverse events</measure>
    <time_frame>from Dose 1 through 1 month after the last dose</time_frame>
    <description>As elicited by investigational site staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants in Phase 2/3 reporting serious adverse events</measure>
    <time_frame>from Dose 1 through 6 months after the last dose</time_frame>
    <description>As elicited by investigational site staff</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥5 to &lt;12 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study</measure>
    <time_frame>1 month after the second dose</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥2 to &lt;5 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in the C4591001 study</measure>
    <time_frame>1 month after the second dose</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ph 2/3 selected-dose participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥6 months to &lt;2 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years in C4591001 study</measure>
    <time_frame>1 month after the second dose</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥5 to &lt;12 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study</measure>
    <time_frame>1 month after the second dose</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥2 to &lt;5 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study</measure>
    <time_frame>1 month after the second dose</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In Phase 2/3 selected-dose participants, the difference in percentages of participants with seroresponse in participants ≥6 months to &lt;2 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001</measure>
    <time_frame>1 month after the second dose</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In Phase 1 participants, SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs</measure>
    <time_frame>Through 7 days after Dose 2</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In evaluable Phase 2/3 participants at selected dose level in each age group, Geometric Mean Titers of SARS-CoV-2 neutralizing titers with no serological or virological evidence of past SARS-CoV-2 infection</measure>
    <time_frame>At baseline (before Dose 1) and 1, 6, 12 (for the original BNT162b2 group only), and 24 (for the original BNT162b2 group only) months after Dose 2</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In evaluable Phase 2/3 participants at the dose level selected in each age group, Geometric Mean Fold Ratio in SARS-CoV-2 serum neutralizing titer from before vaccination to each subsequent time point</measure>
    <time_frame>From before Dose 1 to each subsequent time point after Dose 2</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the evaluable Phase 2/3 selected-dose participants, Ratio of incidence of asymptomatic SARS-CoV-2 infection based on N-binding antibody seroconversion for the active vaccine group to the placebo group without evidence of past SARS-CoV-2 infection</measure>
    <time_frame>Through 6 months after the second dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ph 2/3 LDE participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants ≥5 to &lt;12 years of age to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years of age in the C4591001 study</measure>
    <time_frame>1 month after the second dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ph 2/3 LDE participants, immunobridging of SARS-CoV-2 serum neutralizing titers after 2 doses in participants 12 to &lt;16 years of age to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 25 years of age in the C4591001 study</measure>
    <time_frame>1 month after the second dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ph 2/3 LDE participants, immunobridging of SARS-CoV-2 serum neutralizing titers in participants 16 to &lt;30 years to the geometric mean of SARS-CoV-2 serum neutralizing titers in participants 16 to 55 years from Phase 2/3 of the C4591001 study</measure>
    <time_frame>1 month after the second dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Phase 2/3 lower-dose evaluation participants, the difference in percentages of participants with seroresponse in participants ≥5 to &lt;12 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study</measure>
    <time_frame>1 month after the second dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Phase 2/3 lower-dose evaluation participants, the difference in percentages of participants with seroresponse in participants 12 to &lt;16 years of age and participants 16 to 25 years of age from Phase 2/3 of the C4591001 study</measure>
    <time_frame>1 month after the second dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In lower-dose evaluation participants, the difference in percentages of participants with seroresponse in participants 16 to &lt;30 years of age and participants 16 to 55 years of age from C4591001 study</measure>
    <time_frame>1 month after the second dose</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of confirmed COVID-19 illness, Phase 2/3 selected-dose participants ≥5 to &lt;12 years of age with successful immunobridging, without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group</measure>
    <time_frame>From 7 days after the second dose</time_frame>
    <description>Per 1000 person-years of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of confirmed COVID-19 illness, Phase 2/3 selected-dose participants ≥6 months to &lt;2 years and ≥2 to &lt;5 years of age with successful immunobridging, without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group</measure>
    <time_frame>From 7 days after the second dose</time_frame>
    <description>Per 1000 person-years of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of confirmed COVID-19 illness, Ph 2/3 selected-dose in all age groups (with successful immunobridging) and if did not accrue required cases, without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group</measure>
    <time_frame>From 7 days after the second dose</time_frame>
    <description>Per 1000 person-years of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of confirmed COVID-19 illness, Phase 2/3 selected-dose participants ≥5 to &lt;12 years of age with successful immunobridging, with and without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group</measure>
    <time_frame>From 7 days after the second dose</time_frame>
    <description>Per 1000 person-years of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of confirmed COVID-19, Ph 2/3 selected-dose participants ≥6 months to &lt;2 years and ≥2 to &lt;5 years of age with successful immunobridging, with and without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group</measure>
    <time_frame>From 7 days after the second dose</time_frame>
    <description>Per 1000 person-years of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of confirmed COVID-19 illness, Ph 2/3 selected-dose in all age groups (with successful immunobridging) and if did not accrue required cases, with and without evidence of prior SARS-CoV-2 infection for the active vaccine group to the placebo group</measure>
    <time_frame>From 7 days after the second dose</time_frame>
    <description>Per 1000 person-years of follow-up</description>
  </secondary_outcome>
  <number_of_arms>22</number_of_arms>
  <enrollment type="Anticipated">11422</enrollment>
  <condition>SARS-CoV-2 Infection, COVID-19</condition>
  <arm_group>
    <arm_group_label>Low/Mid-Dose, ≥5 to &lt;12 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low/Mid-Dose (10mcg), 2 doses 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid-Dose, ≥5 to &lt;12 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid-Dose, (20mcg), 2 doses 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose, ≥5 to &lt;12 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-Dose (30mcg), 2 doses 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low/Mid-Dose, ≥2 to &lt; 5 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low/Mid-Dose (10mcg), 2 doses 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid-Dose, ≥2 to &lt;5 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid-Dose, (20mcg), 2 doses 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose, ≥2 to &lt;5 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-Dose, (30mcg), 2 doses 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low/Mid-Dose, ≥6 Months to &lt;2 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low/Mid-Dose, (10mcg), doses 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid-Dose, ≥6 Months to &lt;2 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mid-Dose, (20mcg), doses 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose, ≥6 Months to &lt;2 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-Dose, (30mcg), 2 doses 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Dose, ≥5 to &lt;12 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-Dose (3mcg), 2 doses 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Dose, 16 to &lt;30 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-Dose (3mcg), 2 doses 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low/Mid-Dose, 16 to &lt;30 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low/Mid-Dose (10mcg), 2 doses 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, ≥6 Months to &lt;2 Years</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, ≥2 to &lt;5 Years</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, ≥5 to &lt;12 Years</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Dose, ≥6 Months to &lt;2 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-Dose (3mcg), 2 doses 21 doses apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Dose, ≥2 to &lt;5 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-Dose (3mcg), 2 doses 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose, 12 to &lt;16 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-Dose (3mcg), 2 doses 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low/Mid-Dose, 12 to &lt;16 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low/Mid-Dose (10mcg), 2 doses 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose, 12 to &lt;16 Years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-Dose (30mcg), 2 doses 21 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low/Mid-Dose, ≥5 to &lt;12 Years (Troponin I Testing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low/Mid-Dose (10mcg), 2 doses 21 days apart. A separate cohort of participants to collect serum samples for potential troponin I testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, ≥5 to &lt;12 Years (Troponin I Testing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A separate cohort of participants to collect serum samples for potential troponin I testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological/Vaccine: BNT162b2 10mcg</intervention_name>
    <description>BNT162b2 Low/Mid-Dose (10mcg) level</description>
    <arm_group_label>Low/Mid-Dose, 12 to &lt;16 Years</arm_group_label>
    <arm_group_label>Low/Mid-Dose, 16 to &lt;30 Years</arm_group_label>
    <arm_group_label>Low/Mid-Dose, ≥2 to &lt; 5 Years</arm_group_label>
    <arm_group_label>Low/Mid-Dose, ≥5 to &lt;12 Years</arm_group_label>
    <arm_group_label>Low/Mid-Dose, ≥5 to &lt;12 Years (Troponin I Testing)</arm_group_label>
    <arm_group_label>Low/Mid-Dose, ≥6 Months to &lt;2 Years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BNT162b2 20mcg</intervention_name>
    <description>BNT162b2 Mid-Dose (20mcg) level</description>
    <arm_group_label>Mid-Dose, ≥2 to &lt;5 Years</arm_group_label>
    <arm_group_label>Mid-Dose, ≥5 to &lt;12 Years</arm_group_label>
    <arm_group_label>Mid-Dose, ≥6 Months to &lt;2 Years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BNT162b2 30mcg</intervention_name>
    <description>BNT162b2 High-Dose (30mcg) level</description>
    <arm_group_label>High-Dose, 12 to &lt;16 Years</arm_group_label>
    <arm_group_label>High-Dose, ≥2 to &lt;5 Years</arm_group_label>
    <arm_group_label>High-Dose, ≥5 to &lt;12 Years</arm_group_label>
    <arm_group_label>High-Dose, ≥6 Months to &lt;2 Years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Placebo, ≥2 to &lt;5 Years</arm_group_label>
    <arm_group_label>Placebo, ≥5 to &lt;12 Years</arm_group_label>
    <arm_group_label>Placebo, ≥5 to &lt;12 Years (Troponin I Testing)</arm_group_label>
    <arm_group_label>Placebo, ≥6 Months to &lt;2 Years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological/Vaccine: BNT162b2 3mcg</intervention_name>
    <description>BNT162b2 Low-Dose (3mcg) level</description>
    <arm_group_label>Low-Dose, 16 to &lt;30 Years</arm_group_label>
    <arm_group_label>Low-Dose, ≥2 to &lt;5 Years</arm_group_label>
    <arm_group_label>Low-Dose, ≥5 to &lt;12 Years</arm_group_label>
    <arm_group_label>Low-Dose, ≥6 Months to &lt;2 Years</arm_group_label>
    <arm_group_label>Low-dose, 12 to &lt;16 Years</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Male or female participants ≥6 months to &lt;12 years of age, at the time of&#xD;
             randomization, at Visit 1 for the dose-finding/selected-dose evaluation and for&#xD;
             participants ≥5 to &lt;30 years of age, at the time of randomization, at Visit 1 for the&#xD;
             lower-dose evaluation. For the obtaining-serum-samples-for-potential-troponin&#xD;
             I-testing portion of the study: Male or female participants between ≥5 and &lt;16 years&#xD;
             of age.&#xD;
&#xD;
          2. Participants' parent(s)/legal guardian(s) and participants, as age appropriate, who&#xD;
             are willing and able to comply with all scheduled visits, treatment plan, laboratory&#xD;
             tests, lifestyle considerations, and other study procedures.&#xD;
&#xD;
          3. Healthy participants who are determined by medical history, physical examination, and&#xD;
             clinical judgment of the investigator to be eligible for inclusion in the study.&#xD;
&#xD;
             Note: Healthy participants with preexisting stable disease, defined as disease not&#xD;
             requiring significant change in the therapy or hospitalization for worsening disease&#xD;
             during the 6 weeks before enrollment, can be included.&#xD;
&#xD;
          4. Participants are expected to be available for the duration of the study and whose&#xD;
             parent(s)/legal guardian can be contacted by telephone during study participation.&#xD;
&#xD;
          5. Negative urine pregnancy test for female participants who are biologically capable of&#xD;
             having children.&#xD;
&#xD;
          6. Female participant of childbearing potential or male participant able to father&#xD;
             children who is willing to use a highly effective method of contraception as outlined&#xD;
             in this protocol for at least 28 days after the last dose of study intervention if at&#xD;
             risk of pregnancy with her/his partner; or female participant not of childbearing&#xD;
             potential or male participant not able to father children.&#xD;
&#xD;
          7. The participant or participant's parent(s)/legal guardian is capable of giving signed&#xD;
             informed consent, which includes compliance with the requirements and restrictions&#xD;
             listed in the ICD and in this protocol. Depending on the age of the participant and&#xD;
             according to local requirements, participants will also be asked to provide assent as&#xD;
             appropriate (verbal or written).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Phase 1 only: Past clinical (based on COVID-19 symptoms/signs alone, if a SARS CoV 2&#xD;
             NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs&#xD;
             and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19.&#xD;
&#xD;
          2. Phase 1 only: Known infection with HIV, HCV, or HBV.&#xD;
&#xD;
          3. Receipt of medications intended to prevent COVID-19.&#xD;
&#xD;
          4. Previous or current diagnosis of MIS-C.&#xD;
&#xD;
          5. Other medical or psychiatric condition including recent (within the past year) or&#xD;
             active suicidal ideation/behavior or laboratory abnormality that may increase the risk&#xD;
             of study participation or, in the investigator's judgment, make the participant&#xD;
             inappropriate for the study. Note: This includes both conditions that may increase the&#xD;
             risk associated with study intervention administration or a condition that may&#xD;
             interfere with the interpretation of study results&#xD;
&#xD;
          6. History of severe adverse reaction associated with a vaccine and/or severe allergic&#xD;
             reaction (eg, anaphylaxis) to any component of the study intervention(s).&#xD;
&#xD;
          7. Immunocompromised individuals with known or suspected immunodeficiency, as determined&#xD;
             by history and/or laboratory/physical examination.&#xD;
&#xD;
          8. Individuals with a history of autoimmune disease or an active autoimmune disease&#xD;
             requiring therapeutic intervention, including but not limited to systemic lupus&#xD;
             erythematosus. Note: Stable type 1 diabetes and hypothyroidism are permitted.&#xD;
&#xD;
          9. Bleeding diathesis or condition associated with prolonged bleeding that would, in the&#xD;
             opinion of the investigator, contraindicate intramuscular injection.&#xD;
&#xD;
         10. Female who is pregnant or breastfeeding.&#xD;
&#xD;
         11. Previous vaccination with any coronavirus vaccine.&#xD;
&#xD;
         12. Individuals who receive treatment with immunosuppressive therapy, including cytotoxic&#xD;
             agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or&#xD;
             planned receipt throughout the study. If systemic corticosteroids have been&#xD;
             administered short term (&lt;14 days) for treatment of an acute illness, participants&#xD;
             should not be enrolled into the study until corticosteroid therapy has been&#xD;
             discontinued for at least 28 days before study intervention administration.&#xD;
             Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes)&#xD;
             corticosteroids are permitted.&#xD;
&#xD;
         13. Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60&#xD;
             days before study intervention administration, or receipt of any passive antibody&#xD;
             therapy specific to COVID-19 from 90 days before study intervention administration, or&#xD;
             planned receipt throughout the study.&#xD;
&#xD;
         14. Participation in other studies involving study intervention within 28 days prior to&#xD;
             study entry and/or during study participation.&#xD;
&#xD;
         15. Previous participation in other studies involving study intervention containing LNPs.&#xD;
&#xD;
         16. Participants who are direct descendants (child or grandchild) of investigational site&#xD;
             staff members or Pfizer/BioNTech employees directly involved in the conduct of the&#xD;
             study, site staff otherwise supervised by the investigator, and their respective&#xD;
             family members.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham - School of Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical &amp; Translational Research Unit (CTRU) &amp; Spectrum BioBank, Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials, LLC</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peninsula Research Associates</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Santa Clara</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bayview Research Group, LLC</name>
      <address>
        <city>Valley Village</city>
        <state>California</state>
        <zip>91607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale Center for Clinical Investigation</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Acevedo Clinical Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory Children's Center Illness POD</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Prime</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Solaris Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83646</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric/ Adult Research</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novak Center for Children's Health</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Immunization Research Inpatient Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Professionals</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Hastings</city>
        <state>Nebraska</state>
        <zip>68901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital &amp; Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Physician's Clinic, Spring Valley</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rutgers University</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Specialty Care</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stony Brook University</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke Vaccine and Trials Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Pickett Road</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PriMed Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45419</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Senders Pediatrics</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allegheny Health and Wellness Pavilion</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research-Providence</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates Inc</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ARC Clinical Research at Wilson Parke</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78726</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Driscoll Children's Hospital</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch-Sealy Institute for Vaccine Sciences Clinical Trials Program</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Van Tran Family Practice</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital - Clinical Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Houston Clinical Research Service</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. / Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pediatric Associates of Charlottesville, PLC (Private Pediatric Practice)</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pediatric Research of Charlottesville, LLC</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Research Center</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampere Vaccine Research Clinic</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampere university/ Oulu vaccine research clinic</name>
      <address>
        <city>Oulu</city>
        <state>Pohjois-pohjanmaa</state>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsinki East Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Espoo Vaccine Research Clinic</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsinki South Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MeVac, Meilahti Vaccine Research Center</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jarvenpaa Vaccine Research Center</name>
      <address>
        <city>Jarvenpaa</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kokkola Vaccine Research Clinic</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pori Vaccine Research Clinic</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seinäjoki Vaccine Research Clinic</name>
      <address>
        <city>Seinajoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Turku Vaccine Research Clinic</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IN VIVO Spolka z ograniczona odpowiedzialnoscia</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-048</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.</name>
      <address>
        <city>Krakow</city>
        <zip>30-348</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osrodek Badan Klinicznych Appletreeclinics</name>
      <address>
        <city>Lodz</city>
        <zip>90-349</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GRAVITA Diagnostyka i Leczenie nieplodnosci</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rodzinne Centrum Medyczne LUBMED</name>
      <address>
        <city>Lubon</city>
        <zip>62-030</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Lecznictwa Ambulatoryjnego Michalkowice Jarosz i Partnerzy Spolka Lekarska</name>
      <address>
        <city>Siemianowice Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Przychodnie Medyczne</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Provita 001</name>
      <address>
        <city>Warszawa</city>
        <zip>02-647</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>EAP Centelles</name>
      <address>
        <city>Centelles</city>
        <state>Barcelona</state>
        <zip>08540</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Esplugues De Llobregrat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari General de Catalunya</name>
      <address>
        <city>Sant Cugat del Valles</city>
        <state>Barcelona</state>
        <zip>08195</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Monteprincipe</name>
      <address>
        <city>Boadilla del Monte</city>
        <state>Madrid</state>
        <zip>28660</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Antequera</name>
      <address>
        <city>Antequera</city>
        <state>Malaga</state>
        <zip>29200</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grupo Pediátrico Uncibay</name>
      <address>
        <city>Malaga</city>
        <state>Málaga</state>
        <zip>29015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital HM Puerta del Sur</name>
      <address>
        <city>Mostoles</city>
        <zip>28938</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Hispalense de Pediatria</name>
      <address>
        <city>Sevilla</city>
        <zip>41012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4591007</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus Vaccine</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>RNA Vaccine</keyword>
  <keyword>mRNA Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

